Alpha Cognition INC

Alpha Cognition Inc. has amended its previous filing to confirm the committee assignments for newly appointed director Bethany Sensenig.

Alpha Cognition Inc. has appointed biopharmaceutical industry veteran Bethany Sensenig to its Board of Directors.

Alpha Cognition Inc. has entered into a settlement agreement to resolve future payment obligations related to the Memogain Asset Purchase Agreement.

Alpha Cognition Inc. announced the dates for its 2026 Annual General Meeting of Shareholders and the associated record date.

Alpha Cognition Inc. announced its fiscal year 2025 financial and operational results, highlighting significant commercial momentum for its Alzheimer's treatment, ZUNVEYL, and a strong cash position.

Alpha Cognition Inc. announced that director Len Mertz will not seek re-election at the company's 2026 annual meeting.

Alpha Cognition Inc. (ACOG) announced a significant increase in revenue for the second quarter of 2026, driven by strong product sales of ZUNVEYL, though the company continues to operate at a net loss.

Alpha Cognition Inc. achieved its first product and licensing revenue in Q3 2025, driven by the commercial launch of ZUNVEYL for Alzheimer's disease, despite increased operating expenses and a higher net loss.

Alpha Cognition Inc. reports its first product and licensing revenue following the commercial launch of ZUNVEYL for Alzheimer's, alongside increased net losses and a stated need for additional capital.

Alpha Cognition Inc. reports a net loss of $2.0 million for Q1 2025, with significant revenue growth driven by a new licensing agreement.

Alpha Cognition's Q3 2024 report details a net loss of $8.98 million, but also highlights the FDA approval of ZUNVEYL and a successful $50 million public offering.

Alpha Cognition Inc. reports a net loss of $7.1 million for the six months ended June 30, 2024, while highlighting FDA approval for ZUNVEYL and ongoing efforts to secure additional funding.

Alpha Cognition Inc. commercially launched its Alzheimer's treatment ZUNVEYL, generating initial revenue, but reported a significant increase in net losses for the fiscal year ended December 31, 2025.

Alpha Cognition Inc.'s annual report highlights FDA approval of ZUNVEYL for Alzheimer's and outlines commercialization plans targeting the long-term care market.

Opaleye Management Inc. reported changes in beneficial ownership of Alpha Cognition Inc. common stock on July 31, 2026.

Opaleye Management Inc. reported changes in beneficial ownership of Alpha Cognition Inc. common stock on July 24, 2026.

Opaleye Management Inc. reported changes in beneficial ownership of Alpha Cognition Inc. common stock on July 22, 2026.

Opaleye Management Inc. reported the acquisition of 7,685 shares of Alpha Cognition Inc. across three transactions in June 2026.

Opaleye Management Inc. reported the acquisition of additional shares in Alpha Cognition Inc. through its managed fund and account.

Opaleye Management Inc. has disclosed changes in its beneficial ownership of Alpha Cognition Inc. (ACOG) common stock, acquiring 10,054 shares.

Alpha Cognition Inc. has issued its proxy statement for the 2026 Annual General Meeting to be held on June 16, 2026.

Alpha Cognition Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Alpha Cognition Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Alpha Cognition Inc. announces its Annual General Meeting of Shareholders to be held on June 19, 2025, to discuss financial statements, elect directors, appoint auditors, and approve a new stock and incentive plan.

Alpha Cognition Inc. has filed an amendment to its Form S-1 registration statement, detailing its commercialization strategy for ZUNVEYL and providing updates on its clinical programs and recent corporate activities.

Alpha Cognition has filed a registration statement for the resale of 1.4 million common shares by existing stockholders, following the recent FDA approval of their Alzheimer's drug, ZUNVEYL.

Alpha Cognition Inc. files a registration statement to increase its proposed maximum aggregate offering price by $6,786,409.07 through the sale of additional common shares and pre-funded warrants.

Alpha Cognition USA Inc. enters into an employment agreement with Henry Du as VP, Finance and Accounting, while the company prepares for a public offering.

Alpha Cognition Inc. is offering 2,500,000 common shares and pre-funded warrants to purchase up to 2,500,000 additional common shares, aiming for a Nasdaq Capital Market listing.

Alpha Cognition registers 22.6 million shares for resale, paving the way for potential commercial activities following FDA approval of its Alzheimer's treatment, ZUNVEYL.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting a combined beneficial ownership of 14.22% of Alpha Cognition Inc. common stock.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of 2,895,107 shares of Alpha Cognition Inc. common stock, representing 13.30% of the class.

Manchester Management and associated individuals report a combined beneficial ownership of approximately 4.9% in Alpha Cognition Inc.

Opaleye Management Inc., Opaleye, L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of 2,561,950 shares of Alpha Cognition Inc. common stock, representing 11.77% of the class.

Opaleye Management Inc. and affiliates disclosed an increased beneficial ownership of 10.09% in Alpha Cognition Inc. common stock.

Funicular Funds, LP, along with Cable Car Capital, LP and Jacob Ma-Weaver, has disclosed a 5.1% beneficial ownership stake in Alpha Cognition Inc.